Evaluating Brepocitinib for Treating Skin Sarcoidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of oral brepocitinib in adults diagnosed with cutaneous sarcoidosis. Participants will receive either the active medication or a placebo to determine the drug's impact on their condition. The study focuses on individuals with a specific activity score and confirmed skin biopsy results. It aims to provide insights into a potential new treatment option for this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults subjects
2. Cutaneous sarcoidosis with characteristic skin biopsy histology
3. A CSAMI activity score ≥ 10
4. Weight \> 40 kg to \< 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.

Exclusion Criteria

1. History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix.
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection

Where it's running

• Clinical Trial Site
  Birmingham, Alabama, United States Recruiting
• Clinical Trial Site
  Phoenix, Arizona, United States Recruiting
• Clinical Trial Site
  Tucson, Arizona, United States Recruiting
• Clinical Trial Site
  San Francisco, California, United States Recruiting
• Clinical Trial Site
  New Haven, Connecticut, United States Recruiting
• Clinical Trial Site
  Washington D.C., District of Columbia, United States Recruiting

Study contacts

• Study coordinator: Clinical Trial Administrator
• Email: clinicaltrials@priovant.com
• Phone: (212) 634-9743

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brepocitinib treatment for adults with lichen planopilaris

  This trial will test whether an oral medicine called brepocitinib can safely reduce scalp inflammation and symptoms in adults with lichen planopilaris.

  Recruiting at 61 sites Phase 2/3 Priovant Therapeutics, Inc. · Birmingham, Alabama and 60 other locations · NCT07532603

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.